Bjørnerheim R, Golf S, Hansson V
Medical Department B, Rikshospitalet University Hospital, Olso, Norway.
Naunyn Schmiedebergs Arch Pharmacol. 1990 Oct;342(4):429-35. doi: 10.1007/BF00169460.
To evaluate the effects of chronic pindolol treatment on human myocardial beta-adrenoceptor, membrane preparations from right atrial auricles from patients on chronic pindolol treatment and from patients not treated with beta-blocker were compared with respect to specific binding of [125I]-iodocyanopindolol [( 125I]-ICYP) and adenylate cyclase (AC) activity. Pindolol treatment was associated with a 25% increase in total beta-adrenoceptor density (72.3 vs. 58.3 fmol/mg protein). This increase was due a 40% increase of the beta 1-adrenoceptor subtype (62.2 vs. 44.3 fmol/mg protein), while beta 2-adrenoceptor density was decreased by about 25% (10.0 vs. 14.0 fmol/mg). Isoprenaline 5 mumol/l (9.7 vs. 14.2 pmol/min/mg) and terbutaline 50 mumol/l (4.9 vs. 8.3 pmol/min/mg protein) stimulated adenylate cyclase activity was reduced, whereas fluoride (10 mmol/l) stimulated cAMP production to the same extent in both groups (9.4 vs 9.4 pmol/min/mg protein). Thus, chronic treatment with pindolol was associated with upregulation of the beta 1-adrenoceptors and a down-regulation of the beta 2-adrenoceptors. The total level of beta-adrenoceptors was slightly increased. In spite of this, adenylate cyclase activity and response was reduced.
为评估慢性吲哚洛尔治疗对人心肌β-肾上腺素能受体的影响,比较了慢性服用吲哚洛尔患者及未用β受体阻滞剂治疗患者右心耳的膜制剂,观察其对[125I]-碘氰吲哚洛尔([125I]-ICYP)的特异性结合及腺苷酸环化酶(AC)活性。吲哚洛尔治疗使总β-肾上腺素能受体密度增加25%(分别为72.3和58.3 fmol/mg蛋白)。这种增加是由于β1-肾上腺素能受体亚型增加40%(分别为62.2和44.3 fmol/mg蛋白),而β2-肾上腺素能受体密度下降约25%(分别为10.0和14.0 fmol/mg)。5 μmol/l异丙肾上腺素(分别为9.7和14.2 pmol/min/mg)及50 μmol/l特布他林(分别为4.9和8.3 pmol/min/mg蛋白)刺激的腺苷酸环化酶活性降低,而氟化物(10 mmol/l)刺激的环磷酸腺苷(cAMP)生成在两组中程度相同(分别为9.4和9.4 pmol/min/mg蛋白)。因此,慢性吲哚洛尔治疗与β1-肾上腺素能受体上调及β2-肾上腺素能受体下调相关。β-肾上腺素能受体总水平略有增加。尽管如此,腺苷酸环化酶活性及反应仍降低。